The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervixGOG 240
Gynaecological Malignancies
Cervical Cancer
-
GOG 240
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Bevacizumab
Chemotherapy
Paclitaxel or topotecan or liposomal doxorubicin
In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agentsAURELIA
Gynaecological Malignancies
Ovarian Cancer
-
AURELIA
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Bevacizumab
Paclitaxel + carboplatin
Paclitaxel + carboplatin
In combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancerICON7
Gynaecological Malignancies
Ovarian Cancer
-
ICON7
NEB
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
NEB
Bevacizumab
Paclitaxel + carboplatin
Paclitaxel + carboplatin
In combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced (FIGO stage IIIB, IIIC, IV) epithelial ovarian, fallopian tube, or primary peritoneal cancerICON7
Gynaecological Malignancies
Ovarian Cancer
High risk
ICON7
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Bevacizumab
Gemcitabine + carboplatin
Gemcitabine + carboplatin
In combination with carboplatin and gemcitabine for treatment of adult patients with first recurrence platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agentsOCEANS
Gynaecological Malignancies
Ovarian Cancer
-
OCEANS
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Bevacizumab
Carboplatin + paclitaxel
Paclitaxel and carboplatin (6 cycles)
Incompletely resected stage III and stage IV ovarian cancerGOG-0218
Gynaecological Malignancies
Ovarian Cancer
-
GOG-0218
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Niraparib
-
Placebo
Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
gBRCA
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Niraparib
-
Placebo
Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
non-gBRCA HRD +ve
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Niraparib
-
Placebo
Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChTENGOT-OV16/NOVA
Gynaecological Malignancies
Ovarian Cancer
non-gBRCA
ENGOT-OV16/NOVA
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Trabectedin
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin
In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancerOVA-301
Gynaecological Malignancies
Ovarian Cancer
Platinum sensitive
OVA-301
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Trabectedin
Pegylated liposomal doxorubicin
Pegylated liposomal doxorubicin
In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancerOVA-301
Gynaecological Malignancies
Ovarian Cancer
-
OVA-301
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Olaparib
-
Placebo
Maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy (Phase II)Study 19
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
BRCA mutation
Study 19
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Cediranib
Chemotherapy
Platinum-based chemotherapy + placebo and placebo maintenance
Platinum-sensitive relapsed ovarian cancerICON 6
Gynaecological Malignancies
Ovarian Cancer
-
ICON 6
1
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
1
Pembrolizumab
-
Docetaxel
Locally advanced or metastatic NSCLC with PD-L1 expression ≥1% TPS after ≥1 prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)KEYNOTE-010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥1%
KEYNOTE-010
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Pembrolizumab
-
Docetaxel
Locally advanced or metastatic NSCLC with PD-L1 expression ≥1% TPS after ≥1 prior ChT regimen. Patients with EGFR or ALK-positive tumour mutations should also have received targeted therapy (2 mg/kg and 10mg/kg pooled data)KEYNOTE-010
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥50%
KEYNOTE-010
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nivolumab
-
Docetaxel
Locally advanced or metastatic squamous NSCLC after prior ChTCheckMate 017
Thoracic Malignancies
Non-small-cell Lung Cancer - Squamous cell
-
CheckMate 017
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Nivolumab
-
Docetaxel
Locally advanced or metastatic squamous NSCLC after prior ChTCheckMate 057
Thoracic Malignancies
Non-small-cell Lung Cancer
-
CheckMate 057
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Erlotinib
-
Carboplatin gemcitabine
Locally advanced or metastatic NSCLC with EGFR activating mutationsOPTIMAL, CTONG-0802
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
OPTIMAL, CTONG-0802
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Erlotinib
-
Platinum-based chemotherapy doublet
Locally advanced or metastatic NSCLC with EGFR activating mutationsEURTAC
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
EURTAC
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Gefitinib
-
Carboplatin + paclitaxel
Treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR tyrosine kinase.IPASS
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
IPASS
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Afatinib
-
Cisplatin + pemetrexed
As monotherapy for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s)LUX - Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
LUX - Lung 3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Afatinib
-
Cisplatin + pemetrexed
As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) - Del19/L858R pre-planned subgroup analysisLUX - Lung 3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
LUX - Lung 3
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Osimertinib
-
Platinum/pemetrexed
As monotherapy for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLCAURA3
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
AURA3
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Crizotinib
-
Chemotherapy
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)PROFILE 1007
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
PROFILE 1007
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Crizotinib
-
Pemetrexed + cisplatin or carboplatin
First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)PROFILE 1014
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
PROFILE 1014
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Pemetrexed
-
Placebo
As monotherapy for the maintenance treatment of locally advanced or metastatic NSCLC other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Pemetrexed
Cisplatin
Cisplatin + gemcitabine
In combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
FINAL SCORE
F2c
4
Palliative care
Chemotherapy
Chemotherapy
First-line treatment stage IV NSCLC ECOG<2
Thoracic Malignancies
Non-small-cell Lung Cancer
-
-
4
PRELIMINARY SCORE
NI
ADJUSTMENTS
FINAL SCORE
F2c
4
Pembrolizumab
-
Platinum-based chemotherapy
First line treatment of mNSCLC with tumour PD-L1 expression ≥50% TPS with no EGFR or ALK positive tumour mutationsKEYNOTE-24
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥50%
KEYNOTE-24
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Bevacizumab
Erlotinib
Erlotinib
In combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutationsJO25567
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR+
JO25567
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Therapeutic Indication
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.